INC Research Files Registration Statement for Initial Public Offering
INC Research Holdings, Inc. (INC Research), a leading, global Phase I to IV contract research organization, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to a proposed initial public offering of its common stock. The number of shares to be offered by INC Research
INC Research Holdings, Inc. (INC Research), a leading, global Phase I to IV contract research organization, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to a proposed initial public offering of its common stock. The number of shares to be offered by INC Research and its stockholders and the price range for the offering have not yet been determined. The Company has applied to list its common stock on The NASDAQ Global Market under the ticker symbol “INCR.” INC Research expects to use the net proceeds it receives from the offering to refinance its existing long-term debt as further specified in the registration statement.
Goldman, Sachs & Co. and Credit Suisse are serving as joint lead book-running managers for the offering. Baird, William Blair and Wells Fargo are serving as co-managers for the offering.
The offering will be made only by means of a prospectus. Once available, copies of the preliminary prospectus relating to the offering may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, phone: 866-471-2526, email: [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, phone: 800-221-1037, email: [email protected]
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
